Therapeutic efficacy of RAS inhibitor trametinib using a juvenile myelomonocytic leukemia patient-derived xenograft model
Authors:
Open Access
- 22 April 2024
- journal article
- research article
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 41 (5) , 367-375
Abstract
Juvenile myelomonocytic leukemia (JMML) is an aggressive pediatric leukemia with few effective treatments and poor outcomes even after stem cell transplantation, the only current curative treatment. We developed a JMML patient-derived xenograft (PDX) mouse model and demonstrated the in vivo therapeutic efficacy and confirmed the target of trametinib, a RAS-RAF-MEK-ERK pathway inhibitor, in this model. A PDX model was created through transplantation of patient JMML cells into mice, up to the second generation, and successful engraftment was confirmed using flow cytometry. JMML PDX mice were treated with trametinib versus vehicle control, with a median survival of 194 days in the treatment group versus 124 days in the control group (p = 0.02). Trametinib's target as a RAS pathway inhibitor was verified by showing inhibition of ERK phosphorylation using immunoblot assays. In conclusion, trametinib monotherapy significantly prolongs survival in our JMML PDX model by inhibiting the RAS pathway. Our model can be effectively used for assessment of novel targeted treatments, including potential combination therapies, to improve JMML outcomes.Keywords
Funding Information
- American Society of Hematology
- Salad Cosmo
- Mr. and Mrs. Ray Diamondstone
- Children's Leukemia Research Association
- Academic Senate Research Grant
- Mr. and Mrs. George Davis
- Keaton’s Child Cancer Alliance
- St. Baldrick's Foundation
This publication has 31 references indexed in Scilit:
- Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemiaMolecular Therapy, 2023
- Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartmentLeukemia, 2019
- Azacitidine is effective for targeting leukemia-initiating cells in juvenile myelomonocytic leukemiaLeukemia, 2019
- Study of Molecular Mechanism of the Interaction Between MEK1/2 and Trametinib with Docking and Molecular Dynamic SimulationInterdisciplinary Sciences: Computational Life Sciences, 2018
- Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemiaOncogene, 2016
- The genomic landscape of juvenile myelomonocytic leukemiaNature Genetics, 2015
- Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanomaNature Communications, 2014
- Trametinib2014
- Evolution of human BCR–ABL1 lymphoblastic leukaemia-initiating cellsNature, 2011
- A cell initiating human acute myeloid leukaemia after transplantation into SCID miceNature, 1994